Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders
Top Cited Papers
Open Access
- 2 August 2021
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 93 (1), 24-31
- https://doi.org/10.1136/jnnp-2021-326904
Abstract
Background SARS-CoV-2 seroconversion rate after COVID-19 may be influenced by disease-modifying therapies (DMTs) in patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMO-SD). Objective To investigate the seroprevalence and the quantity of SARS-CoV-2 antibodies in a cohort of patients with MS or NMO-SD. Methods Blood samples were collected in patients diagnosed with COVID-19 between 19 February 2020 and 26 February 2021. SARS-CoV-2 antibody positivity rates and Ig levels (anti-S IgG titre, anti-S IgA index, anti-N IgG index) were compared between DMTs groups. Multivariate logistic and linear regression models were used to estimate the influence of DMTs and other confounding variables on SARS-CoV-2 serological outcomes. Results 119 patients (115 MS, 4 NMO, mean age: 43.0 years) were analysed. Overall, seroconversion rate was 80.6% within 5.0 (SD 3.4) months after infection. 20/21 (95.2%) patients without DMT and 66/77 (85.7%) patients on DMTs other than anti-CD20 had at least one SARS-CoV-2 Ig positivity, while this rate decreased to only 10/21 (47.6%) for patients on anti-CD20 (pConclusions SARS-CoV-2 antibody response was decreased in patients with MS or NMO-SD treated with anti-CD20 therapies. Monitoring long-term risk of reinfection and specific vaccination strategies in this population may be warranted. Trial registration number NCT04568707.Funding Information
- Fondation de France (00113315)
- Federation Internationale de l'Automobile (no Grant / Award Number)
- Donators from Paris Brain Institute - ICM (no Grant / Award Number)
This publication has 35 references indexed in Scilit:
- Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?Neurology Neuroimmunology & Neuroinflammation, 2020
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19The New England Journal of Medicine, 2020
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable TherapiesJAMA Neurology, 2020
- Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter studyZeitschrift für Neurologie, 2018
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisThe New England Journal of Medicine, 2017
- Disease-modifying therapies and infectious risks in multiple sclerosisNature Reviews Neurology, 2016
- A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum DisorderJAMA Neurology, 2013
- Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trialArthritis & Rheumatism, 2009
- Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximabArthritis & Rheumatism, 2009
- Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trialAnnals of Neurology, 2008